Search results for "Pharmacokinetic"

showing 10 items of 474 documents

Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration

2014

Background Anidulafungin is indicated as a first-line treatment for invasive candidiasis in critically ill patients. In the intensive care unit, sepsis is the main cause of acute renal failure, and treatment with continuous renal replacement therapy (CRRT) has increased in recent years. Antimicrobial pharmacokinetics is affected by CRRT, but few studies have addressed the optimal dosage for anidulafungin during CRRT. Patients and methods We included 12 critically ill patients who received continuous venovenous haemodiafiltration to treat acute renal failure. Anidulafungin was infused on 3 consecutive days, starting with a loading dose (200 mg) on Day 1, and doses of 100 mg on Days 2 and 3. …

Microbiology (medical)Antifungal AgentsCritical Illnessmedicine.medical_treatmentHemodiafiltrationAnidulafunginLoading doselaw.inventionSepsisEchinocandinsPharmacokineticslawmedicineHumansCandidiasis InvasivePharmacology (medical)Trough ConcentrationRenal replacement therapyDosingCandidaPharmacologybusiness.industrybacterial infections and mycosesmedicine.diseaseIntensive care unitIntensive Care UnitsInfectious DiseasesAnesthesiaAnidulafunginbusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Fluconazole concentrations in pulmonary tissue and pericardial fluid

1997

In order to investigate the clinical efficacy of the triazole antifungal agent fluconazole (FCA) in the treatment of pulmonary mycosis, in the present study the concentrations of fluconazole in human pulmonary tissue, pericardial fluid and serum were determined at 1, 2, 12 and 13 h after intravenous administration of fluconazole 200 mg. The mean FCA concentrations in the serum were 4.04 mg/l (1 h), 3.82 mg/l (2 h), 2.35 mg/l (12 h) and 2.13 mg/l (13 h). The respective FCA levels in the pulmonary tissue were 4.64 mg/kg, 4.54 mg/kg; 3.50 mg/kg and 3.40 mg/kg and the concentrations in the pericardial fluid were 3.86 mg/l, 3.57 mg/l, 2.35 mg/l and 2.13 mg/l. The FCA concentrations in the pulmon…

Microbiology (medical)Antifungal AgentsMetabolic Clearance Ratemedicine.medical_treatmentTriazoleBiological AvailabilityPharmacologyPericardial Effusionchemistry.chemical_compoundPharmacokineticsCricetinaemedicineAnimalsHumansPericardiumInfusions IntravenousFluconazoleLungMycosisChemotherapyLungbusiness.industryPericardial fluidGeneral Medicinemedicine.diseaseInfectious Diseasesmedicine.anatomical_structurechemistryAnesthesiabusinessFluconazolemedicine.drugInfection
researchProduct

Quantitative In Vivo Microdialysis in Pharmacokinetic Studies

2012

MicrodialysisPharmacokineticsIn vivoChemistryPharmacology
researchProduct

Pharmacokinetics in Drug Discovery

2007

The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery. The review is structured into four sections. The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity. The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound. The third section discusses the most commonly used in vitro methodologies. The fourth and last section examines the various approaches employed towards the pharmacokinetic …

Models MolecularProteomicsDrug discoverybusiness.industryManagement scienceComputer aidPharmaceutical ScienceGenomicsPopulation pharmacokineticsPharmacologyModels BiologicalPharmacokineticsPharmaceutical technologyDrug DesignMajor conclusionAnimalsHumansMedicinePharmacokineticsbusinessProtein BindingADMEJournal of Pharmaceutical Sciences
researchProduct

Pharmacology and safety of tofacitinib in ulcerative colitis.

2020

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

Moderate to severePharmacologyHerpes ZosterArthritis Rheumatoid03 medical and health sciences0302 clinical medicineImmune systemPharmacokineticsPiperidinesNeoplasmsMedicineHerpes Zoster VaccineHumansJanus Kinase InhibitorsDrug InteractionsTofacitinibbusiness.industryImmunogenicityJanus Kinase 3Janus Kinase 1Venous Thromboembolismmedicine.diseaseUlcerative colitisBioavailabilityPyrimidines030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeJanus kinasebusinessGastroenterologia y hepatologia
researchProduct

Combining Pharmacokinetics and Vibrational Spectroscopy: MCR-ALS Hard-and-Soft Modelling of Drug Uptake In Vitro Using Tailored Kinetic Constraints

2022

Raman microspectroscopy is a label-free technique which is very suited for the investigation of pharmacokinetics of cellular uptake, mechanisms of interaction, and efficacies of drugs in vitro. However, the complexity of the spectra makes the identification of spectral patterns associated with the drug and subsequent cellular responses difficult. Indeed, multivariate methods that relate spectral features to the inoculation time do not normally take into account the kinetics involved, and important theoretical information which could assist in the elucidation of the relevant spectral signatures is excluded. Here, we propose the integration of kinetic equations in the modelling of drug uptake…

Multivariate Curve Resolution-Alternating Least SquaresBiological and Chemical PhysicsSystems BiologyMultivariate Curve Resolution-Alternating Least Squares; pharmacokinetics; Raman microspectroscopy; chemometricsGeneral MedicineSpectrum Analysis RamanRaman microspectroscopyKineticsMultivariate AnalysisHumansPharmacokineticsLeast-Squares AnalysisChemometricsBiochemistry Biophysics and Structural Biology
researchProduct

Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs.

2010

Naltrexone (NLX), an opioid antagonist, is widely used in the treatment of opiate addiction, alcoholism and smoking cessation. Its current peroral administration induces various adverse side effects and has limited efficacy since bioavailability and patient compliance are poor. The development of a long-acting drug delivery system of NLX may overcome the current drawbacks and help in the improvement of treatment of addiction. The primary endpoints of this study were: a) to compare the NLX bioavailability and pharmacokinetics after delivering a single transbuccal dose, released by a prototype of intraoral device, versus an intravenous (I.V.) bolus of the same drug dose; b) to verify the func…

Naltrexone HydrochlorideSwineNarcotic AntagonistsSettore MED/50 - Scienze Tecniche Mediche ApplicatePharmaceutical ScienceBiological AvailabilityPharmacologyNaltrexoneBolus (medicine)Drug Delivery SystemsPharmacokineticsSettore MED/28 - Malattie OdontostomatologicheOral administrationMedicineAnimalsNaltrexone hydrochlorideIontophoresiNLXbusiness.industryNarcotic antagonistAdministration BuccalTransmucosal deliveryBuccal administrationEquipment DesignNaltrexoneSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoIntelliDrug intraoral deviceAnesthesiaFemalePorcine buccal mucosabusinessmedicine.drugJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.

2019

Literature data pertaining to the physicochemical, pharmaceutical, and pharmacokinetic properties of ondansetron hydrochloride dihydrate are reviewed to arrive at a decision on whether a marketing authorization of an immediate release (IR) solid oral dosage form can be approved based on a Biopharmaceutics Classification System (BCS)-based biowaiver. Ondansetron, a 5HT3 receptor antagonist, is used at doses ranging from 4 mg to 24 mg in the management of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative treatment. It is a weak base and thus exhibits pH-dependent solubility. However, it is able to meet the criteria of "high solubility" as well as "high permeabi…

NauseaPharmaceutical ScienceAdministration OralBiological Availabilitydissolution02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formBiopharmaceuticsOndansetronExcipients03 medical and health sciencesondansetron hydrochloride dihydrate0302 clinical medicinePharmacokineticsMedicineHumansDissolution testingDosage FormsOndansetron hydrochloridebusiness.industrybiopharmaceutics classification system (BCS)solubility021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemOndansetronbiowaiverTherapeutic Equivalencymedicine.symptompermeability0210 nano-technologybusinessmedicine.drugTablets
researchProduct

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

2015

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role…

NiacinamideErythrocytesPolymers and PlasticsCell SurvivalAdamantaneDrug CompoundingSupramolecular chemistryBioengineeringNanotechnologyAdamantaneAntineoplastic AgentsBinding CompetitiveHemolysisAmphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cellsHCC cellsBiomaterialschemistry.chemical_compoundSurface-Active AgentsIn vivoCell Line TumorAmphiphileMaterials ChemistryHumanschemistry.chemical_classificationCyclodextrinsAqueous solutionCyclodextrinPhenylurea CompoundsSorafenibFluorescenceCombinatorial chemistrydigestive system diseasesNanostructuresBINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLESDrug LiberationKineticsnanoassembliecyclodextrinchemistryDelayed-Action PreparationsProton NMRHepatocytes
researchProduct

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

2021

Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p …

OlanzapineAdultBlood GlucoseMalemedicine.medical_specialtyFarmacologiaWaistBlood PressureWeight GainGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinemedicineHumansPharmacologyValproic Acidmedicine.diagnostic_testbusiness.industrySmokingMiddle Aged030227 psychiatryBlood pressureTreatment OutcomePsychotic DisordersTherapeutic drug monitoringOlanzapineFemalemedicine.symptomDrug MonitoringbusinessWeight gain030217 neurology & neurosurgeryMedicamentsLipoproteinmedicine.drugAntipsychotic Agents
researchProduct